The global hormonal contraceptive market was valued at $13,924 million in 2016, and is estimated to reach $16,018 million by 2023, registering a CAGR of 1.9% from 2017 to 2023. Hormonal contraception is a birth control method, which acts on the endocrine system, and is composed of steroid hormones. Higher concentration of naturally forming hormones such as estrogen and progesterone are used to either prevent ovulation or make unfavorable condition to develop pregnancy. Research Beam Model: Research Beam Product ID: 2958855 5370 USD New
Hormonal Contraceptive Market by Product (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, and Transdermal Patches), Hormone (Progestin-only Contraceptive and Combined Hormonal Contraceptive), Age Group (15-24 Years, 25-34 Years, 35-44 Years, and Above 44 Years), and End User (Hospitals, Household, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023
 
 

Hormonal Contraceptive Market by Product (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, and Transdermal Patches), Hormone (Progestin-only Contraceptive and Combined Hormonal Contraceptive), Age Group (15-24 Years, 25-34 Years, 35-44 Years, and Above 44 Years), and End User (Hospitals, Household, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Category : Healthcare
  • Published On : February   2018
  • Pages : 230
  • Publisher : Allied Market Research
 
 
 

The global hormonal contraceptive market was valued at $13,924 million in 2016, and is estimated to reach $16,018 million by 2023, registering a CAGR of 1.9% from 2017 to 2023. Hormonal contraception is a birth control method, which acts on the endocrine system, and is composed of steroid hormones. Higher concentration of naturally forming hormones such as estrogen and progesterone are used to either prevent ovulation or make unfavorable condition to develop pregnancy.

Increase in adoption of hormonal contraceptives products or birth control methods in the developing countries and incidence of polycystic ovary syndrome (PCOS) are the major driving factors for the growth of the global hormonal contraceptive market. Moreover, rise in population attaining higher education and rise in need to control the ever-growing population in developing regions such as China and India have adopted measures to prevent unwanted pregnancy, which are expected to fuel the market growth. However, availability of alternate contraceptive methods and health risks associated with the use of contraceptives hamper the market growth.

The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, end user, and geography. Based on product, the market is classified into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. Depending on hormone, it is bifurcated into progestin-only contraceptive and combined hormonal contraceptive. By age group, it is categorized into 15–24 years, 25–34 years, 35–44 years, and above 44 years. By end user, it is classified into hospitals, household, and clinics. Geographically, it is analyzed across four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

  • This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product

  • Oral Contraceptive Pills
  • Injectable Birth Control
  • Emergency Contraceptive Pills
  • Vaginal Rings
  • Transdermal Patches

By Hormone

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

By Age Group

  • 15–24 Years
  • 25–34 Years
  • 35–44 Years
  • Above 44 Years

By End User

  • Hospitals
  • Household
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

KEY PLAYERS PROFILED

  • The Female Health Company
  • Teva Pharmaceutical Industries Limited
  • Bayer AG
  • Pfizer, Inc.
  • Mylan N.V.
  • Johnson & Johnson
  • Ansell Ltd.
  • Mayer Laboratories
  • Merck & Co., Inc.
  • Church & Dwight, Co., Inc.

The other players of the hormonal contraceptive market include (companies not profiled in the report):

  • Reckitt Benckiser Plc.
  • Warner Chilcott Company
  • BioSante Pharmaceuticals Inc.
  • HLL Lifecare Limited
  • Boehringer Ingelheim GmbH
  • Watson Pharmaceuticals, Inc.
  • V-Care Pharma Pvt. Ltd.
  • Vardhman Life Care Pvt. Ltd.
  • Cipla Limited

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition and Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Top Player Positioning, 2016
3.4. Porters Five Forces Analysis
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Rise in need for preventing unwanted pregnancy
3.5.1.2. Increasing awareness for contraceptives worldwide
3.5.1.3. Rising usage of oral contraceptives as a preferred method to avoid unplanned pregnancy
3.5.1.4. Technological advancements in contraceptive methods
3.5.1.5. Upsurge in government and NGO initiatives promoting contraceptives

3.5.2. Restrains

3.5.2.1. Health risks associated with the use of contraceptive methods
3.5.2.2. Lack of social acceptance

3.5.3. Opportunities

3.5.3.1. Rise in disposable income and demand for healthy life in emerging economies
3.5.3.2. Presence of large unmet contraceptive needs in emerging Asian and African economies

CHAPTER 4: HORMONAL CONTRACEPTIVE MARKET BY PRODUCT

4.1. Overview

4.1.1. Market Size and Forecast

4.2. Oral Contraceptive Pills

4.2.1. Key market trends & growth opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country

4.3. Injectable Birth Control

4.3.1. Key market trends & growth opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country

4.4. Emergency Contraceptive Pills

4.4.1. Key market trends & growth opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country

4.5. Vaginal Rings

4.5.1. Key market trends & growth opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Analysis, by Country

4.6. Transdermal Patches

4.6.1. Key market trends & growth opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Analysis, by Country

CHAPTER 5: HORMONAL CONTRACEPTIVE MARKET BY HORMONE

5.1. Overview

5.1.1. Market Size and Forecast

5.2. Progestin-only Contraceptive

5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country

5.3. Combined Hormonal Contraceptive

5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country

CHAPTER 6: HORMONAL CONTRACEPTIVE MARKET BY AGE GROUP

6.1. Overview

6.1.1. Market Size and Forecast

6.2. 15-24 years

6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country

6.3. 25-34 years

6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country

6.4. 35-44 years

6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country

6.5. Above 44 years

6.5.1. Market Size and Forecast
6.5.2. Market Analysis, by Country

CHAPTER 7: HORMONAL CONTRACEPTIVE MARKET BY END USERS

7.1. Overview

7.1.1. Market Size and Forecast

7.2. Hospitals

7.2.1. Market Size and Forecast
7.2.2. Market Analysis, by Country

7.3. Household

7.3.1. Market Size and Forecast
7.3.2. Market Analysis, by Country

7.4. Clinics

7.4.1. Market Size and Forecast
7.4.2. Market Analysis, by Country

CHAPTER 8: HORMONAL CONTRACEPTIVE MARKET BY GEOGRAPHY

8.1. Overview

8.1.1. Market Size and Forecast

8.2. North America

8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, by Product Type
8.2.3. Market Size and Forecast, by Hormone
8.2.4. Market Size and Forecast, by Age Group
8.2.5. Market Size and Forecast, by End Users
8.2.6. Market Size and Forecast, by Country

8.2.6.1. U.S. Market Size and Forecast, by Product Type
8.2.6.2. U.S. Market Size and Forecast, by Hormone
8.2.6.3. U.S. Market Size and Forecast, by Age Group
8.2.6.4. U.S. Market Size and Forecast, by End Users
8.2.6.5. Canada Market Size and Forecast, by Product Type
8.2.6.6. Canada Market Size and Forecast, by Hormone
8.2.6.7. Canada Market Size and Forecast, by Age Group
8.2.6.8. Canada Market Size and Forecast, by End Users
8.2.6.9. Mexico Market Size and Forecast, by Product Type
8.2.6.10. Mexico Market Size and Forecast, by Hormone
8.2.6.11. Mexico Market Size and Forecast, by Age Group
8.2.6.12. Mexico Market Size and Forecast, by End Users

8.3. Europe

8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, by Product Type
8.3.3. Market Size and Forecast, by Hormone
8.3.4. Market Size and Forecast, by Age Group
8.3.5. Market Size and Forecast, by End Users
8.3.6. Market Size and Forecast, by Country

8.3.6.1. Germany Market Size and Forecast, by Product Type
8.3.6.2. Germany Market Size and Forecast, by Hormone
8.3.6.3. Germany Market Size and Forecast, by Age Group
8.3.6.4. Germany Market Size and Forecast, by End Users
8.3.6.5. France Market Size and Forecast, by Product Type
8.3.6.6. France Market Size and Forecast, by Hormone
8.3.6.7. France Market Size and Forecast, by Age Group
8.3.6.8. France Market Size and Forecast, by End Users
8.3.6.9. UK Market Size and Forecast, by Product Type
8.3.6.10. UK Market Size and Forecast, by Hormone
8.3.6.11. UK Market Size and Forecast, by Age Group
8.3.6.12. UK Market Size and Forecast, by End Users
8.3.6.13. Italy Market Size and Forecast, by Product Type
8.3.6.14. Italy Market Size and Forecast, by Hormone
8.3.6.15. Italy Market Size and Forecast, by Age Group
8.3.6.16. Italy Market Size and Forecast, by End Users
8.3.6.17. Spain Market Size and Forecast, by Product Type
8.3.6.18. Spain Market Size and Forecast, by Hormone
8.3.6.19. Spain Market Size and Forecast, by Age Group
8.3.6.20. Spain Market Size and Forecast, by End Users
8.3.6.21. Rest of Europe Market Size and Forecast, by Product Type
8.3.6.22. Rest of Europe Market Size and Forecast, by Hormone
8.3.6.23. Rest of Europe Market Size and Forecast, by Age Group
8.3.6.24. Rest of Europe Market Size and Forecast, by End Users

8.4. Asia-Pacific

8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, by Product Type
8.4.3. Market Size and Forecast, by Hormone
8.4.4. Market Size and Forecast, by Age Group
8.4.5. Market Size and Forecast, by End Users
8.4.6. Market Size and Forecast, by Country

8.4.6.1. Japan Market Size and Forecast, by Product Type
8.4.6.2. Japan Market Size and Forecast, by Hormone
8.4.6.3. Japan Market Size and Forecast, by Age Group
8.4.6.4. Japan Market Size and Forecast, by End Users
8.4.6.5. China Market Size and Forecast, by Product Type
8.4.6.6. China Market Size and Forecast, by Hormone
8.4.6.7. China Market Size and Forecast, by Age Group
8.4.6.8. China Market Size and Forecast, by End Users
8.4.6.9. Australia Market Size and Forecast, by Product Type
8.4.6.10. Australia Market Size and Forecast, by Hormone
8.4.6.11. Australia Market Size and Forecast, by Age Group
8.4.6.12. Australia Market Size and Forecast, by End Users
8.4.6.13. India Market Size and Forecast, by Product Type
8.4.6.14. India Market Size and Forecast, by Hormone
8.4.6.15. India Market Size and Forecast, by Age Group
8.4.6.16. India Market Size and Forecast, by End Users
8.4.6.17. South Korea Market Size and Forecast, by Product Type
8.4.6.18. South Korea Market Size and Forecast, by Hormone
8.4.6.19. South Korea Market Size and Forecast, by Age Group
8.4.6.20. South Korea Market Size and Forecast, by End Users
8.4.6.21. Rest of Asia-Pacific Market Size and Forecast, by Product Type
8.4.6.22. Rest of Asia-Pacific Market Size and Forecast, by Hormone
8.4.6.23. Rest of Asia-Pacific Market Size and Forecast, by Age Group
8.4.6.24. Rest of Asia-Pacific Market Size and Forecast, by End Users

8.5. LAMEA

8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, by Product Type
8.5.3. Market Size and Forecast, by Hormone
8.5.4. Market Size and Forecast, by Age Group
8.5.5. Market Size and Forecast, by End Users
8.5.6. Market Size and Forecast, by Country

8.5.6.1. Brazil Market Size and Forecast, by Product Type
8.5.6.2. Brazil Market Size and Forecast, by Hormone
8.5.6.3. Brazil Market Size and Forecast, by Age Group
8.5.6.4. Brazil Market Size and Forecast, by End Users
8.5.6.5. Saudi Arabia Market Size and Forecast, by Product Type
8.5.6.6. Saudi Arabia Market Size and Forecast, by Hormone
8.5.6.7. Saudi Arabia Market Size and Forecast, by Age Group
8.5.6.8. Saudi Arabia Market Size and Forecast, by End Users
8.5.6.9. South Africa Market Size and Forecast, by Product Type
8.5.6.10. South Africa Market Size and Forecast, by Hormone
8.5.6.11. South Africa Market Size and Forecast, by Age Group
8.5.6.12. South Africa Market Size and Forecast, by End Users
8.5.6.13. Rest of LAMEA Market Size and Forecast, by Product Type
8.5.6.14. Rest of LAMEA Market Size and Forecast, by Hormone
8.5.6.15. Rest of LAMEA Market Size and Forecast, by Age Group
8.5.6.16. Rest of LAMEA Market Size and Forecast, by End Users

CHAPTER 9: COMPANY PROFILES

9.1. Ansell Limited

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance

9.2. Bayer AG

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. Church & Dwight Co. Inc.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance

9.4. Johnson & Johnson

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance

9.5. Mayer Laboratories Inc.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments

9.6. Merck & Co. Inc.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance

9.7. Mylan N.V.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. Pfizer Inc.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. Teva Pharmaceutical Industries Ltd.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. The Female Health Company

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Business performance

LIST OF TABLES

TABLE 01. GLOBAL HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 02. ORAL HORMONAL CONTRACEPTIVE PILLS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 03. INJECTABLE HORMONAL CONTRACEPTIVE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. EMERGENCY HORMONAL CONTRACEPTIVE PILLS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. VAGINAL RINGS HORMONAL CONTRACEPTIVE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. TRANSDERMAL PATCHES HORMONAL CONTRACEPTIVE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 07. GLOBAL HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 08. PROGESTIN-ONLY CONTRACEPTIVE HORMONAL CONTRACEPTIVE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 09. COMBINED HORMONAL CONTRACEPTIVE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 11. HORMONAL CONTRACEPTIVE MARKET FOR 15-24 YEARS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. HORMONAL CONTRACEPTIVE MARKET, FOR 25-34 YEARS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. HORMONAL CONTRACEPTIVE SOFTWARE MARKET, FOR 35-44 YEARS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. HORMONAL CONTRACEPTIVE MARKET, FOR ABOVE 44 YEARS, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 16. HORMONAL CONTRACEPTIVE MARKET BY HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. HORMONAL CONTRACEPTIVE MARKET BY HOUSEHOLD, BY REGION, 2016-2023 ($MILLION)
TABLE 18. HORMONAL CONTRACEPTIVE MARKET BY CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 19. HORMONAL CONTRACEPTIVE MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 25. U.S. HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 26. U.S. HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 27. U.S. HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 28. U.S. HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 29. CANADA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 30. CANADA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 31. CANADA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 32. CANADA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 33. MEXICO HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 34. MEXICO HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 35. MEXICO HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 36. MEXICO HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 37. EUROPE HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 38. EUROPE HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 39. EUROPE HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 40. EUROPE HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 41. EUROPE HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. GERMANY HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 43. GERMANY HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 44. GERMANY HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 45. GERMANY HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 46. FRANCE HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 47. FRANCE HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 48. FRANCE HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 49. FRANCE HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 50. UK HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 51. UK HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 52. UK HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 53. UK HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 54. ITALY HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 55. ITALY HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 56. ITALY HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 57. ITALY HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 58. SPAIN HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 59. SPAIN HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 60. SPAIN HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 61. SPAIN HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 62. REST OF EUROPE HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 63. REST OF EUROPE HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 64. REST OF EUROPE HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 65. REST OF EUROPE HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 66. ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 67. ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 68. ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 69. ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 70. ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 71. JAPAN HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 72. JAPAN HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 73. JAPAN HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 74. JAPAN HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 75. CHINA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 76. CHINA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 77. CHINA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 78. CHINA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 79. AUSTRALIA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 80. AUSTRALIA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 81. AUSTRALIA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 82. AUSTRALIA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 83. INDIA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 84. INDIA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 85. INDIA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 86. INDIA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 87. SOUTH KOREA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 88. SOUTH KOREA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 89. SOUTH KOREA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 90. SOUTH KOREA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 95. LAMEA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 96. LAMEA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 97. LAMEA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 98. LAMEA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 99. LAMEA HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 100. BRAZIL HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 101. BRAZIL HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 102. BRAZIL HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 103. BRAZIL HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 104. SAUDI ARABIA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 105. SAUDI ARABIA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 106. SAUDI ARABIA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 107. SAUDI ARABIA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 108. SOUTH AFRICA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 109. SOUTH AFRICA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 110. SOUTH AFRICA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 111. SOUTH AFRICA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 112. REST OF LAMEA HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 113. REST OF LAMEA HORMONAL CONTRACEPTIVE MARKET, BY HORMONE, 2016-2023 ($MILLION)
TABLE 114. REST OF LAMEA HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2016-2023 ($MILLION)
TABLE 115. REST OF LAMEA HORMONAL CONTRACEPTIVE MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 116. ANSELL: COMPANY SNAPSHOT
TABLE 117. ANSELL: OPERATING SEGMENTS
TABLE 118. BAYER: COMPANY SNAPSHOT
TABLE 119. BAYER: OPERATING SEGMENTS
TABLE 120. CHURCH & DWIGHT: COMPANY SNAPSHOT
TABLE 121. CHURCH & DWIGHT: OPERATING SEGMENTS
TABLE 122. J&J: COMPANY SNAPSHOT
TABLE 123. J&J: OPERATING SEGMENTS
TABLE 124. MAYER: COMPANY SNAPSHOT
TABLE 125. MAYER: OPERATING PRODUCT CATEGORIES
TABLE 126. MERCK: COMPANY SNAPSHOT
TABLE 127. MERCK: OPERATING SEGMENTS
TABLE 128. MYLAN: COMPANY SNAPSHOT
TABLE 129. MYLAN: OPERATING SEGMENTS
TABLE 130. PFIZER: COMPANY SNAPSHOT
TABLE 131. PFIZER: OPERATING SEGMENTS
TABLE 132. TEVA: COMPANY SNAPSHOT
TABLE 133. TEVA: OPERATING SEGMENTS
TABLE 134. THE FEMALE HEALTH COMPANY: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 01. GLOBAL HORMONAL CONTRACEPTIVE MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2016
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. HIGH THREAT OF SUBSTITUTION
FIGURE 08. HIGH COMPETITIVE RIVALRY
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF ORAL HORMONAL CONTRACEPTIVE PILLS MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF INJECTABLE HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF EMERGENCY HORMONAL CONTRACEPTIVE PILLS MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VAGINAL RINGS HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TRANSDERMAL PATCHES HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PROGESTIN-ONLY CONTRACEPTIVE HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMBINED HORMONAL CONTRACEPTIVE MARKET, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE MARKET FOR 15-24 YEARS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE MARKET, FOR 25-34 YEARS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE SOFTWARE MARKET, FOR 35-44 YEARS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE MARKET, FOR ABOVE 44 YEARS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE MARKET BY HOSPITALS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE MARKET BY HOUSEHOLD, BY COUNTRY, 2016 & 2023 (%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HORMONAL CONTRACEPTIVE MARKET BY CLINICS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 23. ANSELL: NET SALES, 2015-2017 ($MILLION)
FIGURE 24. ANSELL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. ANSELL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. BAYER: NET SALES, 2015-2017 ($MILLION)
FIGURE 27. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. BAYER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. CHURCH & DWIGHT: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. CHURCH & DWIGHT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. J&J: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. MYLAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 38. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 40. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 42. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 43. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 45. THE FEMALE HEALTH COMPANY: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. THE FEMALE HEALTH COMPANY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

PURCHASE OPTIONS
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

REQUEST SAMPLE    ASK FOR DISCOUNT